Incyte Corp. Announces CMS Medicaid Pricing Agreement for Jakafi

What Happened Incyte Corporation announced on August 31, 2026 (8-K filed) that it has entered into an agreement with the U.S. Centers for Medicare & Medicaid Services (CMS) to improve patient access by allowing state Medicaid programs to obtain Jakafi and Jakafi XR at prices aligned with a defined group of other advanced, industrialized nations. The company also said it expects not to be subject to certain future CMS pricing mandates, including the proposed GUARD and GLOBE models. The filing states the agreement is not expected to affect Incyte’s 2026 financial guidance or have a material impact on its future financial outlook.

Key Details

• Products covered: Jakafi and Jakafi XR (Incyte’s drugs referenced in the agreement).
• Counterparty: U.S. Centers for Medicare & Medicaid Services (CMS).
• Timing: Agreement disclosed in Form 8-K filed August 31, 2026; signed by Richard Hoffman, Executive VP & General Counsel.
• Financial impact: Company does not expect the agreement to change 2026 guidance or have a material impact on future outlook; expects relief from certain proposed CMS models (GUARD and GLOBE).

Why It Matters This agreement addresses Medicaid pricing and patient access for Incyte’s key therapies while preserving the company’s current financial guidance. For investors, the filing signals management expects limited near-term financial disruption from CMS pricing changes and clarifies that Incyte seeks to avoid broader mandatory pricing programs (GUARD/GLOBE) that could have more significant implications if applied. The change may alter pricing terms specifically for state Medicaid programs, but per the company, it should not materially affect reported results for 2026.